RT Journal Article
SR Electronic
T1 Persistence of antibody and T cell responses to the Sinopharm/BBIBP-CorV vaccine in Sri Lankan individuals
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.14.21265030
DO 10.1101/2021.10.14.21265030
A1 Jeewandara, Chandima
A1 Aberathna, Inoka Sepali
A1 Pushpakumara, Pradeep Darshana
A1 Kamaladasa, Achala
A1 Guruge, Dinuka
A1 Wijesinghe, Ayesha
A1 Gunasekera, Banuri
A1 Tanussiya, Shyrar
A1 Kuruppu, Heshan
A1 Ranasinghe, Thushali
A1 Dayarathne, Shashika
A1 Dissanayake, Osanda
A1 Gamalath, Nayanathara
A1 Ekanayake, Dinithi
A1 Jayamali, Jeewantha
A1 Jayathilaka, Deshni
A1 Dissanayake, Madushika
A1 Jayadas, Tibutius Thanesh
A1 Mudunkotuwa, Anushika
A1 Somathilake, Gayasha
A1 Harvie, Michael
A1 Nimasha, Thashmi
A1 Danasekara, Saubhagya
A1 Wijayamuni, Ruwan
A1 Schimanski, Lisa
A1 Rijal, Pramila
A1 Tan, Tiong K.
A1 Dong, Tao
A1 Townsend, Alain
A1 Ogg, Graham S.
A1 Malavige, Gathsaurie Neelika
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.14.21265030.abstract
AB Background To determine the kinetics and persistence of immune responses following the Sinopharm/BBIBP-CorV, we investigated immune responses in a cohort of Sri Lankan individuals.Methods SARS-CoV-2 specific total antibodies were measured in 20-to-39 year (n=61), 40-to-59-year and those >60 years of age (n=22) by ELISA, 12 weeks after the second dose of the vaccine. ACE2 receptor blocking antibodies (ACE2R-Ab), antibodies to the receptor binding domain (RBD) of the ancestral virus (WT) and variants of concern, were measured in a sub cohort. T cell responses and memory B cell responses were assessed by ELISpot assays.Results 193/203 (95.07%) of individuals had detectable SARS-CoV-2 specific total antibodies, while 67/110 (60.9%) had ACE2R-Ab. 14.3% to 16.7% individuals in the 20 to 39 age groups had detectable antibodies to the RBD of the WT and VOC, while the positivity rates of those >60 years of age was <10%. 14/49 (28.6%) had IFNγ ELISpot responses to overlapping peptides of the spike protein, while memory B cell responses were detected in 9/20 to the S1 recombinant protein. The total antibody levels and ACE2R-Ab declined after 2 to 12 weeks from the second dose, while ex vivo T cell responses remained unchanged. The decline in ACE2R-Ab levels was significant among the 40 to 59 (p=0.0007) and ≥60 (p=0.005) age groups.Conclusions Antibody responses declined in all age groups, especially in those >60 years, while T cell responses persisted. The effect of waning of immunity on hospitalization and severe disease should be assessed by long term efficacy studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical trial.Funding StatementWe are grateful to the Allergy, Immunology and Cell Biology Unit, University of Sri Jayewardenepura; the NIH, USA (grant number 5U01AI151788-02), UK Medical Research Council and the Foreign and Commonwealth Office for support. T.K.T. is funded by the Townsend-Jeantet Charitable Trust (charity number 1011770) and the EPA Cephalosporin Early Career Researcher Fund. A.T. are funded by the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS), China (grant no. 2018-I2M-2-002).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Review Committee of University of Sri Jayewardenepura.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.